Pioneering, proven pain treatment for knee OA
Arthrosamid® — The first and only synovial scaffold administered via a single injectable for long-lasting pain relief.
~ 528 million
people worldwide were living with osteoarthritis in 2019; an increase of 113% since 1990.
The Problem
Despite osteoarthritis (OA) being the most common type of arthritis and the fastest-growing cause of disability worldwide, the treatment area has seen minimal progression in the last 20 years. With so little known about exactly what causes knee OA, a permanent cure has yet to be discovered.
Redefining treatment for knee OA, without surgery
Arthrosamid® is a non-biodegradable 2.5 iPAAG injectable implant that delivers long-lasting pain relief — improving the quality of life for patients with knee OA.
Pioneering
Arthrosamid® is a first-in-class synovial scaffold delivered as a single, minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.
Proven
Researched for more than two decades, Arthrosamid® has been proven to maintain a statistically significant reduction in pain in patients with knee OA 4 years after treatment.
Pain Relief Treatment
A single, minimally invasive, long-lasting knee OA treatment, Arthrosamid® has demonstrated an improvement in quality of life with patients in clinical trials reporting a reduction in pain by Week 4 — and lasting over 4 years.
Our Results
In all our studies, Arthrosamid® exceeds the MCID of 9 points and improvement is maintained up to 4 years after a single injection.
WOMAC pain subscale change from baseline across studies.
344 million people living with osteoarthritis experience severity levels (moderate or severe) that could benefit from rehabilitation.
Patient Rehabilitation Programme
We are delighted to introduce our patient rehabilitation programme. Click on the link below to see the videos.